NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

DHR

Danaher Corp

Jul 15 • 04:00PM ET

192.86

Dollar change -4.89
Percentage change -2.47	%

Healthcare • Diagnostics & Research • USA • NYSE

Peers: GE HON MMM ROK KEYS ABT TMO MTD BSX

| Held by: VTI VOO SPY IVV VTV XLV VIG VHT MOAT IWD

Scroll to Statements

Index	S&P 500	P/E	37.39	EPS (ttm)	5.16	Insider Own	8.87%	Shs Outstand	715.60M	Perf Week	-3.90%
Market Cap	138.02B	Forward P/E	22.52	EPS next Y	8.56	Insider Trans	-1.96%	Shs Float	652.19M	Perf Month	-5.97%
Enterprise Value	153.62B	PEG	4.57	EPS next Q	1.64	Inst Own	81.45%	Short Float	1.21%	Perf Quarter	2.19%
Income	3.77B	P/S	5.79	EPS this Y	2.94%	Inst Trans	0.76%	Short Ratio	2.06	Perf Half Y	-17.96%
Sales	23.82B	P/B	2.71	EPS next Y	11.21%	ROA	4.63%	Short Interest	7.90M	Perf YTD	-15.98%
Book/sh	71.06	P/C	69.25	EPS next 5Y	8.19%	ROE	7.22%	52W High	281.70 -31.54%	Perf Year	-21.69%
Cash/sh	2.78	P/FCF	28.16	EPS past 3/5Y	-15.01% 9.03%	ROIC	5.63%	52W Low	171.00 12.78%	Perf 3Y	-17.51%
Dividend Est.	1.21 (0.63%)	EV/EBITDA	20.43	Sales past 3/5Y	-6.76% 5.92%	Gross Margin	59.80%	Volatility	2.82% 2.41%	Perf 5Y	17.98%
Dividend TTM	1.18 (0.61%)	EV/Sales	6.45	EPS Y/Y TTM	-12.75%	Oper. Margin	21.67%	ATR (14)	5.40	Perf 10Y	229.70%
Dividend Ex-Date	Jun 27, 2025	Quick Ratio	1.05	Sales Y/Y TTM	-9.19%	Profit Margin	15.81%	RSI (14)	41.34	Recom	1.24
Dividend Gr. 3/5Y	8.74% 9.69%	Current Ratio	1.43	EPS Q/Q	-8.94%	SMA20	-3.31%	Beta	0.74	Target Price	244.91
Payout	20.42%	Debt/Eq	0.35	Sales Q/Q	-0.95%	SMA50	-1.72%	Rel Volume	1.18	Prev Close	197.75
Employees	63000	LT Debt/Eq	0.31	Earnings	Jul 22 BMO	SMA200	-12.25%	Avg Volume	3.83M	Price	192.86
IPO	Dec 10, 1969	Option/Short	Yes / Yes	EPS/Sales Surpr.	15.52% 3.04%	Trades		Volume	4,521,728	Change	-2.47%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-11-25	Upgrade	Scotiabank	Sector Perform → Sector Outperform	$275
Apr-10-25	Upgrade	Barclays	Equal Weight → Overweight	$205
Mar-21-25	Upgrade	Goldman	Neutral → Buy	$260
Mar-14-25	Upgrade	Stifel	Hold → Buy	$260
Feb-03-25	Downgrade	Raymond James	Outperform → Mkt Perform
Dec-23-24	Initiated	Scotiabank	Sector Perform
Dec-19-24	Initiated	Guggenheim	Buy	$275
Dec-13-24	Upgrade	BofA Securities	Neutral → Buy	$290
Oct-31-24	Upgrade	Wolfe Research	Peer Perform → Outperform	$285
Oct-01-24	Initiated	Stephens	Overweight	$315
Aug-28-24	Initiated	Wells Fargo	Equal Weight	$280
Jun-03-24	Resumed	Jefferies	Buy	$295
Apr-17-24	Upgrade	HSBC Securities	Hold → Buy	$280
Jan-24-24	Downgrade	Barclays	Overweight → Equal Weight	$240
Dec-18-23	Initiated	HSBC Securities	Hold
Dec-13-23	Resumed	Wolfe Research	Peer Perform
Dec-07-23	Downgrade	Goldman	Buy → Neutral	$215 → $205
Jul-19-23	Initiated	Raymond James	Outperform	$270
May-01-23	Initiated	SVB Securities	Outperform	$300
Apr-26-23	Downgrade	BofA Securities	Buy → Neutral	$310 → $250

Show Previous Ratings

Jul-13-25 02:48AM	Danaher (DHR) Teams Up to Advance Precision Medicine Diagnostics (Insider Monkey)
Jul-11-25 09:38AM	CoreWeave initiated, Texas Instruments upgraded: Wall Street's top analyst calls (The Fly)
Jul-08-25 06:24AM	Liquid Handling Systems Market Insights Report 2025-2030 \| Advancements in Microplate Reagent Dispensers, Transformation in Genomics, Importance in Drug Discovery & Development, Lab Automation (GlobeNewswire)
Jul-05-25 10:43AM	Jim Cramer Says "Danaher Can Make a Comeback" (Insider Monkey)
Jul-03-25 04:21AM	Biopharmaceuticals Manufacturing Consumables Testing Market 2025-2030: Thermo Fisher Scientific, Danaher Corporation, and Merck Lead (GlobeNewswire)
09:50AM	Loading…
Jul-01-25 09:50AM	Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio (Zacks)
Jun-30-25 11:34AM	Is Danaher's M&A Premium Already Priced In? (GuruFocus.com)
01:09AM	Danaher appoints Martin Stumpe as chief technology and AI officer (MedTech Dive)
Jun-28-25 12:20PM	Jim Cramer on Danaher: "This Stock Has Been Such a Disappointment for Me" (Insider Monkey)
Jun-27-25 11:40AM	CVS vs. DHR: Which Stock Is the Better Value Option? (Zacks)
07:35AM	Danaher Appoints Martin Stumpe as Chief Technology and AI Officer (PR Newswire)
07:30AM	Danaher appoints Greg Milosevich to Executive Vice President, Life Sciences (PR Newswire)
Jun-25-25 09:01PM	Lightning Round: I am horrified at what is happening at Danaher, says Jim Cramer (CNBC TV)
12:27PM	Opus Water Launches -- Serving the Water, Wastewater and Industrial Process Fluids Industries (PR Newswire)
12:23PM	Danaher Corporation (DHR) Is "Fool's Gold," Bemoans Jim Cramer (Insider Monkey)
10:47AM	Loading…
10:47AM	Oligonucleotide Synthesis Market Research and Global Forecast Report 2025-2030: Rising Emphasis on Advancing Drug Delivery and Scalable Synthesis Technologies for Oligonucleotide-Based Therapeutics (GlobeNewswire)
Jun-24-25 11:52AM	Danaher Corporation (DHR): A Bull Case Theory (Insider Monkey)
Jun-20-25 09:45AM	Why Danaher (DHR) is a Top Growth Stock for the Long-Term (Zacks)
Jun-17-25 04:30PM	Danaher Schedules Second Quarter 2025 Earnings Conference Call (PR Newswire)
12:10PM	5 Must-Read Analyst Questions From Danaher's Q1 Earnings Call (StockStory)
Jun-13-25 04:31PM	Top Analyst Reports for Eli Lilly, Home Depot & SAP (Zacks)
Jun-11-25 11:40AM	CVS vs. DHR: Which Stock Should Value Investors Buy Now? (Zacks)
02:00AM	Tesla Stock Has Lost Its Trump Bump. How to Play the Shares Now. (Barrons.com)
Jun-05-25 12:02AM	3 Reasons to Avoid DHR and 1 Stock to Buy Instead (StockStory)
Jun-02-25 07:00AM	Software Launches for SCIEX OS Ecosystem to Help Scientists Accelerate Discoveries and Streamline Lab Operations (Business Wire)
07:00AM	SCIEX Sets a New Standard in Accurate Mass Quantitation With the ZenoTOF 8600 System and New Software Collaborations (Business Wire)
07:00AM	SCIEX and Evosep expand access to standardized proteomics for Pharma and Biotech with new reseller agreement (Business Wire)
May-30-25 11:50AM	Danaher Partners With AstraZeneca to Support Precision Medicine (Zacks)
10:12AM	Danaher and AstraZeneca to develop diagnostic tools and tests (Medical Device Network)
May-29-25 11:11PM	Danaher Corporation (DHR) Launches Partnership with AstraZeneca PLC (AZN) to Scale Next-Gen Precision Medicine Tests (Insider Monkey)
04:30PM	Loading…
04:30PM	Danaher Announces Diagnostic Development and Commercialization Partnership to Scale Precision Medicine (PR Newswire)
May-26-25 11:40AM	CVS or DHR: Which Is the Better Value Stock Right Now? (Zacks)
May-22-25 04:40PM	Was Jim Cramer Right About Danaher Corporation (DHR)? (Insider Monkey)
11:30AM	Why Is Danaher (DHR) Down 4.8% Since Last Earnings Report? (Zacks)
09:54AM	Here's Why Investors Should Consider Retaining Danaher Stock Now (Zacks)
May-21-25 04:09PM	Danaher, Illumina, Globalstar, and Insperity Shares Plummet, What You Need To Know (StockStory) -5.54%
May-15-25 07:15PM	Daniel Loeb's Strategic Moves: Danaher Corp Exit Impacts Portfolio by -5.87% (GuruFocus.com)
01:00PM	Aldevron and Integrated DNA Technologies Manufacture Worlds First mRNA-based Personalized CRISPR Therapy (Business Wire)
May-09-25 05:25PM	Danaher Corporation (DHR): Among Billionaire Lei Zhang's Stock Picks with Huge Upside Potential (Insider Monkey) +5.85%
11:40AM	CVS vs. DHR: Which Stock Is the Better Value Option? (Zacks)
06:32AM	Is Danaher Corporation (DHR) the Best Medical Device Stock to Buy Now? (Insider Monkey)
12:33AM	1 S&P 500 Stock with Competitive Advantages and 2 to Keep Off Your Radar (StockStory)
May-08-25 05:58PM	From Apple to GM, Tariffs to Cost Companies Tens of Billions (Bloomberg)
May-07-25 04:15PM	Danaher to Present at Bank of America Securities Healthcare Conference (PR Newswire)
01:25PM	Danaher Corporation (DHR): A Bull Case Theory (Insider Monkey)
04:55AM	Fidelity Select Health Care Portfolio Q1 2025 Commentary (Seeking Alpha)
May-06-25 04:15PM	Danaher Announces Quarterly Dividend (PR Newswire)
May-02-25 09:30AM	Third Point Q1 2025 Investor Letter (Seeking Alpha)
04:00AM	Danaher: Q1 Beat Fails To Trigger Guidance Upgrade (Seeking Alpha)
May-01-25 02:26PM	Danaher Corporation (DHR): Among Charles Akre's and John Neff's Stock Picks With Huge Upside Potential (Insider Monkey)
Apr-30-25 10:15AM	The Davenport Core Leaders Fund Q1 2025 Commentary (Seeking Alpha)
Apr-29-25 11:30AM	Baron Health Care Fund Q1 2025 Top Contributors And Detractors (Seeking Alpha)
10:07AM	Kytopen and Aldevron Expedite Cell Therapy Manufacturing Through Their Collaborative CRISPR-mediated Cellular Engineering Workflow (PR Newswire)
08:25AM	Jim Cramer on Danaher Corporation (DHR): From Best to Worst Amid China Struggles (Insider Monkey)
Apr-28-25 08:16AM	Danaher Corporation (DHR): Among Billionaire Ken Fisher's Healthcare Stock Picks with Massive Upside Potential (Insider Monkey)
Apr-27-25 02:22PM	Baron Health Care Fund Q1 2025 Shareholder Letter (Seeking Alpha)
03:01AM	Revvity (RVTY) Q1 Earnings Report Preview: What To Look For (StockStory)
Apr-25-25 08:03PM	Analyst Report: Danaher Corporation (Morningstar Research)
Apr-24-25 04:54AM	Danaher predicts $350M tariff hit, moves to mitigate impact on profits (MedTech Dive)
Apr-23-25 05:30PM	Danaher price target lowered to $240 from $260 at Goldman Sachs (TipRanks)
12:10PM	Danaher Corporation (DHR): Among Top Stocks in Bill Gates' Portfolio with Huge Upside Potential (Insider Monkey)
11:40AM	BLCO or DHR: Which Is the Better Value Stock Right Now? (Zacks)
03:01AM	Danaher Corp (DHR) Q1 2025 Earnings Call Highlights: Strong Bioprocessing Growth Amidst Mixed ... (GuruFocus.com)
Apr-22-25 10:30PM	Q1 2025 Danaher Corp Earnings Call (Thomson Reuters StreetEvents)
09:35PM	DHR Q1 Earnings: Bioprocessing Momentum and Tariff Strategy Drive Guidance Above Expectations (StockStory)
09:35PM	DHR Q1 Earnings Call: Bioprocessing Momentum and Tariff Strategy Drive Guidance Above Expectations (StockStory)
04:05PM	S&P Behemoth Danaher Surges On Plans To Navigate Pharma-Tied Tariffs (Investor's Business Daily)
02:22PM	Danaher (DHR) Stock Trades Up, Here Is Why (StockStory)
12:14PM	Danaher Q1 Earnings Beat Estimates, Life Sciences Sales Down Y/Y (Zacks)
11:09AM	Danaher Corporation (DHR) Q1 2025 Earnings Call Transcript (Seeking Alpha)
10:00AM	Analyst Report: Danaher Corporation (Morningstar Research)
09:30AM	Danaher (DHR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
09:28AM	How S&P 500 Stock Danaher Plans To Offset Tariffs After Its 'Solid' First-Quarter Report (Investor's Business Daily)
09:28AM	Danaher Makes A Bullish Move On 'Solid' Report, Promising Tariffs Plan (Investor's Business Daily)
07:10AM	Danaher (DHR) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
06:17AM	Danaher (NYSE:DHR) Surprises With Q1 Sales, Next Quarter's Sales Guidance is Optimistic (StockStory)
06:07AM	Danaher: Q1 Earnings Snapshot (Associated Press Finance)
06:00AM	Danaher Reports First Quarter 2025 Results (PR Newswire)
Apr-21-25 10:16AM	Danaher Gears Up to Post Q1 Earnings: Is a Beat in Store? (Zacks)
08:04AM	Danaher (DHR) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
Apr-19-25 01:25AM	Dividend Champion, Contender, And Challenger Highlights: Week Of April 20 (Seeking Alpha)
Apr-16-25 09:15AM	Exploring Analyst Estimates for Danaher (DHR) Q1 Earnings, Beyond Revenue and EPS (Zacks)
Apr-15-25 01:49PM	Parnassus Core Select ETF Q1 2025 Commentary (Seeking Alpha)
10:00AM	Danaher (DHR) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
Apr-13-25 05:41PM	Is Danaher Corporation (DHR) the Best Medical Stock to Buy According to Billionaires? (Insider Monkey)
Apr-11-25 08:28AM	Jim Cramer Calls Out Danaher (DHR) CEO: "Time to Step Up or Step Aside" (Insider Monkey)
03:20AM	Akre Focus Fund Q1 2025 Commentary (Seeking Alpha)
Apr-10-25 01:30PM	Analyst Report: Danaher Corporation (Morningstar Research) -5.80%
11:44AM	Here's How Danaher Corporation (DHR) Benefits from Switching Costs (Insider Monkey)
Apr-08-25 02:22PM	Danaher Corporation (DHR): Among Stocks with Buy Ratings that Hedge Funds Love (Insider Monkey)
Apr-07-25 07:28PM	Analyst Report: Danaher Corporation (Morningstar Research)
12:50PM	Tariffs And Tactics: Agilent's Path Through Trade Disruption (Seeking Alpha)
Apr-04-25 09:06PM	Lightning Round: Robinhood has more downside from here, says Jim Cramer (CNBC TV) -8.15%
11:57AM	Danaher Gains From Strength in the Diagnostics Unit Amid Headwinds (Zacks)
09:25AM	Andvari Associates Q1 2025 Letter (Seeking Alpha)
Apr-03-25 07:51AM	Is Danaher Corporation (DHR) a Well-Positioned Company Heading into 2025? (Insider Monkey)
Apr-02-25 07:30AM	3 Wide-Moat Dividend Stars For A Championship Portfolio (Seeking Alpha)
12:10AM	Lord Abbett Dividend Growth Fund Q4 2024 Commentary (Seeking Alpha)
Apr-01-25 04:59PM	Top Analyst Reports for Amazon, Oracle & Merck (Zacks)
04:55PM	Danaher Corporation (DHR): One of the Best Healthcare Stocks to Buy According to Billionaires (Insider Monkey)

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, and Diagnostics. The Biotechnology segment includes bioprocessing, discovery, and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
List Teri	Director	Jul 02 '25	Option Exercise	59.34	3,928	233,088	24,667	Jul 07 05:00 PM
RALES STEVEN M	Chairman	May 12 '25	Sale	196.74	1,250,000	245,919,391	3,105,808	May 14 05:19 PM
RALES STEVEN M	Officer	May 12 '25	Proposed Sale	194.82	1,250,000	243,525,000		May 12 09:30 PM
Raskas Daniel	Former Officer	May 02 '25	Proposed Sale	201.03	7,053	1,417,865		May 02 10:45 AM
Riley Christopher Paul	Executive Vice President	Apr 30 '25	Option Exercise	76.47	7,801	596,542	30,984	May 01 05:01 PM
Riley Christopher Paul	Executive Vice President	Apr 30 '25	Sale	198.00	15,805	3,129,424	15,179	May 01 05:01 PM
Riley Christopher Paul	Officer	Apr 30 '25	Proposed Sale	198.00	15,805	3,129,421		Apr 30 03:41 PM
Glenstone Foundation	See Remarks	Apr 24 '25	Proposed Sale	196.50	598,281	117,562,216		Apr 24 05:28 PM
King William	Former Officer	Mar 11 '25	Proposed Sale	207.14	64,697	13,401,340		Mar 11 04:03 PM
King William	Officer	Feb 21 '25	Proposed Sale	209.97	114,351	24,010,531		Feb 21 04:18 PM
Sabeti Pardis C	former Board of Directors	Feb 18 '25	Proposed Sale	204.28	4,337	885,953		Feb 18 01:04 PM
SPOON ALAN G	Director	Feb 07 '25	Option Exercise	59.34	3,928	233,088	121,068	Feb 10 05:00 PM
SPOON ALAN G	Director	Feb 07 '25	Sale	206.46	550	113,553	120,518	Feb 10 05:00 PM
SPOON ALAN G	Director	Feb 07 '25	Proposed Sale	206.46	550	113,553		Feb 07 03:34 PM
Ellis Brian W	Senior Vice President - GC	Jan 30 '25	Option Exercise	58.59	5,700	333,963	25,930	Jan 31 05:00 PM
Ellis Brian W	Senior Vice President - GC	Jan 30 '25	Sale	224.13	5,700	1,277,541	20,230	Jan 31 05:00 PM
Ellis Brian W	Officer	Jan 30 '25	Proposed Sale	224.13	5,700	1,277,542		Jan 30 12:56 PM
Raskas Daniel	SVP - Corporate Development	Nov 26 '24	Option Exercise	58.59	26,318	1,541,972	41,543	Nov 27 05:01 PM
Raskas Daniel	SVP - Corporate Development	Nov 26 '24	Sale	236.59	26,318	6,226,497	15,225	Nov 27 05:01 PM
Raskas Daniel	SVP - Corporate Development	Nov 25 '24	Sale	238.00	8,370	1,992,060	15,225	Nov 27 05:01 PM
Raskas Daniel	Officer	Nov 26 '24	Proposed Sale	236.59	26,318	6,226,496		Nov 26 04:40 PM
Raskas Daniel	Officer	Nov 25 '24	Proposed Sale	238.00	8,370	1,992,060		Nov 25 12:04 PM
Glenstone Foundation	See Remarks	Nov 05 '24	Proposed Sale	247.76	100,000	24,776,000		Nov 05 04:01 PM
Weidemanis Joakim	Former Director	Oct 23 '24	Proposed Sale	254.95	17,659	4,502,216		Oct 23 01:10 PM
Couchara Georgeann	SVP, Human Resources	Aug 26 '24	Sale	268.37	952	255,483	4,212	Aug 27 05:04 PM
Couchara Georgeann	Officer	Aug 26 '24	Proposed Sale	268.37	952	255,483		Aug 26 04:40 PM
Glenstone Foundation	See Remarks	Aug 13 '24	Proposed Sale	267.20	47,937	12,808,766		Aug 13 04:05 PM
Blair Rainer	President & CEO	Jul 31 '24	Sale	280.00	9,007	2,521,960	97,983	Aug 02 05:00 PM
FILLER LINDA	Director	Aug 01 '24	Option Exercise	59.34	3,928	233,088	45,077	Aug 02 05:00 PM
FILLER LINDA	Director	Aug 01 '24	Sale	279.50	3,928	1,097,876	41,149	Aug 02 05:00 PM
McGrew Matthew	EVP & Chief Financial Officer	Aug 01 '24	Option Exercise	62.85	16,172	1,016,410	45,579	Aug 02 05:00 PM
McGrew Matthew	EVP & Chief Financial Officer	Aug 01 '24	Sale	279.84	16,172	4,525,555	29,407	Aug 02 05:00 PM
McGrew Matthew	Officer	Aug 01 '24	Proposed Sale	279.84	16,172	4,525,555		Aug 01 04:28 PM
FILLER LINDA	Director	Aug 01 '24	Proposed Sale	279.50	3,928	1,097,876		Aug 01 12:27 PM
Blair Rainer	Officer	Jul 31 '24	Proposed Sale	280.00	9,007	2,521,960		Jul 31 04:26 PM
Ellis Brian W	Senior Vice President - GC	Jul 25 '24	Sale	275.16	9,600	2,641,536	20,230	Jul 26 05:03 PM
Raskas Daniel	SVP - Corporate Development	Jul 25 '24	Sale	270.51	14,507	3,924,352	23,595	Jul 26 05:03 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DHR

Danaher Corp

Upgrade your FINVIZ experience